Kiniksa Pharmaceuticals International plc

For the period ended Dec 31, 2024. Filed Feb 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 25, 2025

KNSA$98.76+5.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share and per share amounts)


· · December 31, · · December 31,
· 2024 · 2023
Assets · ·
Current assets: · · ·
Cash and cash equivalents	$183,581	$107,954
Short-term investments	60,046	98,417
Accounts receivable, net	41,724	21,266
Inventory	26,364	31,122
Prepaid expenses and other current assets	20,084	17,538
Total current assets	331,799	276,297
Property and equipment, net	662	734
Operating lease right-of-use assets	10,376	11,931
Other long-term assets	10,315	827
Intangible asset, net	16,250	17,250
Deferred tax assets	211,151	219,283
Total assets	$580,553	$526,322

Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable	$2,039	$8,246
Accrued collaboration expenses	48,157	16,939
Accrued expenses	32,355	27,728
Deferred revenue	—	307
Operating lease liabilities	1,993	2,253
Other current liabilities	16,077	8,193
Total current liabilities	100,621	63,666
Non-current liabilities:
Non-current deferred revenue	31,811	11,954
Non-current operating lease liabilities	7,862	10,005
Other long-term liabilities	1,823	1,858
Total liabilities	142,117	87,483
Commitments and contingencies (Note 16)
Shareholders’ equity:
Class A ordinary shares, par value of $0.000273235 per share; 41,881,319 shares and 35,781,373 shares issued and outstanding as of December 31, 2024 and 2023, respectively	11	10
Class B ordinary shares, par value of $0.000273235 per share; 1,795,158 shares issued and outstanding as of December 31, 2024 and 2023	1	1
Class A1 ordinary shares, $0.000273235 par value; 12,781,964 shares and 16,826,468 issued and outstanding as of December 31, 2024 and 2023, respectively	4	5
Class B1 ordinary shares, $0.000273235 par value; 16,057,618 shares issued and outstanding as of December 31, 2024 and 2023	4	4
Additional paid-in capital	959,722	916,763
Accumulated other comprehensive income (loss)	(163)	6
Accumulated deficit	(521,143)	(477,950)
Total shareholders’ equity	438,436	438,839
Total liabilities and shareholders’ equity	$580,553	$526,322

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.